POLA1 and diffuse large B-cell lymphoma: A larger sample size would be required to draw any conclusions; however, it is suggests that, for the time being, pola-R-CHP should not be used for double-hit/triple-hit disease, which comprises 5-10% of all DLBCL cases (34).